Evidence map›Paper›PMID 37963669›Full record

ArticleLupus science & medicine2023

Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay and

Devyn Zaminski, Amit Saxena, Peter Izmirly, Jill P Buyon, H Michael Belmont

Open access · goldAbstract read
In one paragraph

Article in Lupus science & medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Devyn ZaminskiNYU Grossman School of Medicine, New York City, New York, USA devyn.zaminski@nyulangone.org.ORCID 0000-0002-4396-3523
Amit SaxenaRheumatology, NYU Grossman School of Medicine, New York City, New York, USA.ORCID 0000-0003-0098-1083
Peter IzmirlyRheumatology, NYU Grossman School of Medicine, New York City, New York, USA.ORCID 0000-0001-5445-2182
Jill P BuyonRheumatology, NYU Grossman School of Medicine, New York City, New York, USA.ORCID 0000-0002-3852-7129
H Michael BelmontRheumatology, NYU Grossman School of Medicine, New York City, New York, USA.ORCID 0000-0000-3389-2976
New York University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAnti-dsDNA antibodies (anti-dsDNA) are a component of all classification schemes in SLE and comprise one of the domains in validated activity indices. Anti-dsDNA is frequently measured commercially by an enzyme immunoassay (EIA) or

methodsAll patients fulfilled the classification criteria for SLE by at least one of the validated schemes: American College of Rheumatology, Systemic Lupus Erythematosus International Collaborating Clinics and/or American College of Rheumatology/European League Against Rheumatism classification criteria. Patients with one or more simultaneously paired anti-dsDNA by multiplex EIA and CLIFT were identified. Analysis of concordance or discordance, titre comparability of assays and association with hybrid SLE Disease Activity Index score, prevalence of lupus nephritis (LN), ability to predict a flare and classification criteria was performed.

results207 patients were simultaneously tested by EIA and CLIFT at least once for anti-dsDNA, generating 586 paired results. 377 pairs were concordant and 209 were discordant. 41 of 207 patients always had discordant paired results and 39 patients always had results with titre discordance. In 100 patients with LN, 60 were positive by EIA and 72 by CLIFT. Sensitivities and specificities for patients with LN versus patients without LN were EIA 60% and 47%, and CLIFT 72% and 37%, respectively. 42 patients had flare assessment within 90 days of their paired result. Six of seven patients with mild flares and all four patients with severe flares had concordant positive results.

conclusionOur data demonstrate that discordance of positivity between both assays for anti-dsDNA is relatively common, occurring in a fifth of patients overall and a third of visits. EIA positivity is associated with LN less often than CLIFT positivity. With the significant discordance of results between anti-dsDNA assays, obtaining both CLIFT and EIA assays may be beneficial for classification and routine monitoring of SLE.

Indexed as

Lupus Erythematosus, SystemicLupus NephritisAntibodies, AntinuclearCrithidiaDNAFluorescent Antibody TechniqueHumansImmunoassayAntibodies, Antinuclearanti-dsDNA autoantibodyDNAAntibodiesAutoantibodiesAutoimmune DiseasesLupus Erythematosus, SystemicLupus Nephritis

Identifiers

PMID37963669
PMCPMC10649789
OpenAlexW4388706765

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.